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ABSTRACT
Background: Serous cystic neoplasms of the pancreas are regarded as a benign entity
with rare malignant potential. Surgical resection is generally considered curative.
Objective: To perform the largest single institution review of patients who underwent
surgical resection for serous cystic neoplasms of the pancreas in the hopes of guiding
future management.
Methods: Between June 1988 and January 2005, 158 patients with serous cystic
neoplasms of the pancreas underwent surgical resection. A retrospective analysis was
performed. Univariate and multivariate models were used to determine factors
influencing perioperative morbidity and mortality. Major complications were defined as
pancreatic fistula or anastomotic leak, postoperative bleed, retained operative material, or
death. Minor complications were defined as wound infection, postoperative
obstruction/ileus requiring TPN, delayed gastric emptying, arrhythmia, or other infection.
Results: The mean age of the patients was 62.1 years, with 75% being female. The
majority of patients were symptomatic at presentation (63%), with abdominal pain as the
most common symptom. Of the 158 patients, 75 underwent distal pancreatectomy, 65
underwent pancreaticoduodenectomy, 9 underwent central pancreatectomy, 5 underwent
local resection or enucleation, and 4 underwent total pancreatectomy. Mean tumor
diameter was 5.1 cm. Mean operative time was 277.5 minutes. Mean postoperative
length of hospital stay was 11 days. One patient was diagnosed at presentation with
serous cystadenocarcinoma. The remaining 157 patients were initially diagnosed with
benign serous cystadenoma. One of three patients with locally aggressive benign disease

2.
later presented with metastatic disease. Resection margins for all 158 patients were
negative for tumor, and only 1 (0.6%) showed lymph node involvement. There was one
intraoperative death. The incidence of major perioperative complications was 18%,
while the incidence of minor complications was 33%. Men were significantly more
likely to experience minor perioperative complications (OR = 3.74, P = .008), while
patients greater than 65 years showed a trend toward fewer major complications (OR =
0.36, P = .09).
Conclusions: Serous cystic neoplasms of the pancreas which are surgically resected are
typically seen in asymptomatic women, as 5 cm neoplasms which are predominantly
benign. Most are resected via either a left or right sided pancreatectomy with low
mortality risk, but with notable major or minor morbidity. Cystadenocarcinoma is a rare
finding on initial resection of serous cystic neoplasms. However, initial pathology
specimens exhibiting benign but locally aggressive neoplasia may indicate an increased
likelihood of recurrence or metachronous metastasis.
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INTRODUCTION
Serous cystic neoplasms (SCNs) of the pancreas are almost always benign. They
are one of the most common primary pancreatic cystic neoplasms, and are distinguished
from mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms
(IPMNs) (1). SCNs constitute 10-15% of all cystic masses of the pancreas and 1-2% of
all pancreatic neoplasms (2,3). However, SCNs are being increasingly diagnosed with
more widespread use and improving technology of imaging techniques (4,5). These
neoplasms show a predilection for middle-aged and older women and are often
discovered incidentally (6). Symptoms are frequently non-specific, with abdominal pain
being the most common, occurring in 50-60% of all cases (7). Computed tomography is
thought to be the diagnostic test of choice to properly identify this tumor type (8). SCNs
are typically unifocal and present as large, well-demarcated, often honeycombed cystic
masses which can grow as large as 25 cm. Diffuse or multifocal disease is uncommon.
The cysts are loculated, consist of mucin-free serous fluid, and are surrounded by
cuboidal or flattened epithelium. (9)
Unlike MCNs and IPMNs, SCNs are generally regarded as almost always benign,
though their potential for malignant conversion remains a topic of debate (10). Due in
large part to the uncertainty over malignant potential and the natural history of the
disease, currently there is no accepted standard of treatment or follow-up for SCNs. For
many, observation and routine surveillance are preferred (11). Some investigators
recommend complete resection of all SCNs because of the perceived malignant potential
of the disease, the relative frequency of symptoms and complications, and the challenge
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of an accurate preoperative diagnosis (2,12,13). Those that utilize a selective approach
advocate for resection in the setting of tumors that are symptomatic, poorly defined, and
larger sized (7,14). Indeed, symptomatology appears to be the predominant and only
universally accepted indication for operative intervention. In all cases, resection is
considered curative, with no postoperative surveillance recommended.
The goals of our large (158 patients) single institution review were to evaluate
clinical parameters, pathologic features, and overall patient outcome following resection
of SCNs of the pancreas, in the hopes of guiding future management.
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METHODS
Between June 1988 and January 2005, 158 patients with serous cystic neoplasms
of the pancreas underwent surgical resection. A retrospective analysis of a database was
performed. The study was approved by the Institutional Review Board for Human
Research and complied with Health Insurance Portability and Accountability Act
(HIPAA) regulations.
Major complications were defined as pancreatic fistula or anastomotic leak,
postoperative bleed, retained operative material, or death. Minor complications were
defined as wound infection, postoperative obstruction/ileus requiring TPN, bowel
obstruction responsive to conservative non-operative treatment, delayed gastric emptying,
arrhythmia, or other infection. Follow-up data were collected from postoperative
admissions and/or clinic visits. Univariate and multivariate models were used to
determine factors influencing perioperative morbidity and mortality. The chi square test
was used for comparison between categorical outcome variables versus categorical
independent variables, while t test was used to compare between continuous outcome
variables versus categorical independent variables. Multiple logistic regression was used
in final analysis. Statistical significance was defined as p<0.05. Statistical analysis was
performed using Stata 9. Data are given as mean +/- standard deviation, where
appropriate.
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RESULTS
Demographics
Table 1 outlines the patient population in our series. The mean age of patients
was 62.1. + 13.3 years with most patients being non-Hispanic whites (81%). The
majority of patients (75%) were female. There was no significant difference in age of
presentation between males and females.
Presentation
Most patients presented with symptoms (64%). The most common symptoms
were abdominal pain (74%), weight loss (22%), nausea/vomiting (10%), jaundice (6%),
and GI bleed (3%). Men tended to be symptomatic more than women (45% of men
versus 34% of women, not significant). Symptoms did not correlate with location or size
of tumor. Of 158 patients, 66 (42%) underwent a computed tomography (CT) scan at our
institution while the remaining were referred and treated with outside studies. Figure 1
shows two representative CT scans of patients with SCNs.
Operative and Postoperative Course
All patients in this series were treated operatively. Of the 158 patients, 75 (47%)
underwent distal pancreatectomy for neoplasm of the body or tail of the pancreas, 65
(41%) underwent pancreaticoduodenectomy for right-sided tumors, 9 (6%) underwent
central pancreatectomy for neoplasms of the neck or proximal body, 5 (3%) underwent
local resection or enucleation, and 4 (3%) underwent total pancreatectomy for neoplasms
extensively involving the gland. The average operative time was 277.5 minutes. The
average transfusion requirement was 0.8 + 3.9 units of packed red blood cells. There was
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one operative death due to intraoperative hemorrhage from visceral vessels. Overall, the
incidence of major complications was 18% while the incidence of minor complications
was 33%. The most common major complication was pancreatic leak or fistula with an
incidence of 13%. Men were significantly more likely to have minor complications than
women (OR = 3.75, p = .008). Patients >65 years of age also showed a trend toward
fewer major complications (OR = 0.36, p = .088). Table 2 and Table 3 describe
complications by age and gender respectively. Mean postoperative length of hospital
stay was 11.3 (SD = 8.9 days).
Pathology
For 158 resected tumors, the mean tumor size was 5.1 cm + 3.7 cm. Tumors were
located in the head (42%), body or tail (48%), proximal neck or body (7%), and with
diffuse involvement of the entire gland (3%). Tumor size did not significantly vary by
tumor location. Of all 158 patients, one patient at primary resection was noted to have
biopsy proven serous cystic neoplasm of the liver and was therefore diagnosed with
serous cystadenocarcinoma. The remaining 157 patients were diagnosed at primary
resection with serous cystadenoma of the pancreas. Of these 157 patients, 3 were noted
in final pathology report to have “locally aggressive disease” on histologic examination.
One of these 3 patients recurred 13 years later with disease in the liver and retroperitoneal
tissue and was therefore diagnosed with serous cystadenocarcinoma.
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DISCUSSION
Classified as a benign neoplasm, serous cystic neoplasm (SCN) of the pancreas is
the most common primary cystic neoplasm of the pancreas and accounts for 1-2% of all
primary pancreatic neoplasms (1). SCNs had long been classified with mucinous cystic
neoplasms, until Compagno and Oertel as well as Hodgkinson and others defined and
separated serous from mucinous cystic neoplasms (15, 16). They recognized that the
mucinous variants such as mucinous cystic neoplasms (MCNs) and intraductal papillary
mucinous neoplasms (IPMNs) have a significantly greater malignant potential than
SCNs.
George et al. first introduced a malignant variant known as serous
cystadenocarcinoma (10). There have since been multiple case reports of malignant SCN
histologically indistinguishable from benign SCN of the pancreas but marked by
malignant behavior, most commonly invasive or metastatic disease (12,17-23). One
study suggested that up to 3% of reported SCNs were in fact malignant or had malignant
potential (8). This malignant variant is defined by the presence of metastases to
extrapancreatic organs or tissues (24). Vascular and perineural invasion, and local
invasion into the duodenum or stomach, are not criteria for the diagnosis of malignancy.
There currently exists no consensus for management of SCNs. Many advocate
simple surveillance given the almost universally benign nature of the disease and the
relative morbidity and mortality associated with resection (11). However, a schedule of
surveillance which adequately defines when expectant management should yield to
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intervention has yet to be agreed upon. Furthermore, because other cystic neoplasms of
the pancreas have significant malignant potential, it is imperative that the diagnosis of
SCN be certain before committing to expectant management and surveillance. Others
support a selective approach to resection based on symptoms, tumor size, or
indeterminate preoperative diagnosis, among other factors (13,14). There continue to be
those who support resection of all SCNs. They cite the real, albeit rare, malignant
potential, the risk of an incorrect preoperative diagnosis, and the potential for symptoms
and complications. Resection is generally considered curative and no postoperative
monitoring is advocated.
Here we report the largest single institution experience with SCNs to date. The
mean age of the 158 patients was 62.1 years with 75% being female (Table 1). This is
consistent with previous studies which have also shown a predilection for the disease in
middle aged to elderly females. Most patients were symptomatic at presentation (64%).
Among symptomatic patients, the most common symptoms were abdominal pain (74%),
weight loss (22%), nausea/vomiting (10%), jaundice (6%), and GI bleed (3%). The
proportion of symptomatic patients is similar to or higher than that found in most other
reviews. (8,14,15) The higher rate of symptomatic patients may partly be explained by
the extensive referral nature of the practice at Johns Hopkins. In our series, 41% of the
SCNs arose in the head of the pancreas, 48% in the body or tail, 6% in the neck or
proximal body, and only 3% of lesions exhibited diffuse involvement of the entire gland.
Mean tumor diameter was 5.1 cm, similar to the size found in Tseng et al.’s
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contemporary series (14). All resection margins were negative, with only one SCN
exhibiting lymph node involvement. There was one intraoperative death, due to
excessive hemorrhage. In our experience, surgery for these lesions carried minimum
mortality risk (0.6%) but notable major (18%) and minor (33%) morbidity risk. This risk
of complications approximates the risk of pancreatic surgery for other conditions (such as
adenocarcinoma of the pancreas) but the mortality rate for resection of SCN is less (25).
It is worth noting that males had a significantly greater risk of experiencing minor
complications than women. The reasons for this difference are not immediately apparent
and warrant further investigation. No patient died of his or her disease. This fact, in
conjunction with the aforementioned risks of surgery, would support a cautious approach
to the resection of these neoplasms.
In our series, only 0.6% (1/158) of the patients with an SCN presented with
metastatic disease. This patient presented initially with multifocal disease in the pancreas
and liver, and was therefore diagnosed with a serous cystadenocarcinoma. Indeed, after
resection of her pancreatic tumor, she returned to clinic one year later with extensive
growth of a biopsy proven SCN in the liver which was nonoperable. Remarkably, both
her primary and the liver metastases had a histologically bland appearance, lacking both
architectural and cytologic atypia. An additional 3 patients in this study were noted to
have “locally aggressive” neoplasms at the time of initial resection. These neoplasms
were histologically identical to the more benign behaving tumors, but showed locally
aggressive behavior by growing into neighboring structures (Figure 2). Margins were
negative for these tumors. One of these patients returned in follow-up 13 years after
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resection with biopsy proven recurrence in the liver and retroperitoneal soft tissue.
Again, both the primary and the liver metastases had a histologically bland appearance,
lacking both architectural and cytologic atypia. As this represented an extrapancreatic
recurrence, the diagnosis for this patient was adjusted to reflect a serous
cystadenocarcinoma. Thus, a total of two of the 158 patients (1.3%) in this series either
presented with or ultimately developed metastatic disease.
Currently, resection for SCN is considered curative with no follow-up beyond
postoperative care recommended. Here we report one case of recurrence following
resection of the primary tumor. This tumor exhibited locally aggressive behavior at time
of initial resection. Only two of the remaining 157 resected specimens exhibited a
similar pattern. Locally aggressive growth therefore may offer an important clue as to
which neoplasms have the potential to recur as cystadenocarcinoma. It will be interesting
to follow the 2 additional patients whose tumors exhibited locally aggressive growth.
Their lack of metastatic disease or recurrence may be explained by the fact that their
primary resections were relatively recent (1999 and 2000) as compared to the primary
resection for the patient whose disease later recurred (1992). Further follow-up of this
tumor characteristic is warranted, and may offer a tool in determining a subpopulation of
patients who do not have metastases at presentation, but for whom additional follow-up
surveillance is warranted.
The proper management of patients with a SCN remains elusive. The first step is
to distinguish this lesion from the more aggressive and premalignant lesions: IPMNs and
MCNs. Beyond that, there are divergent paths. Based on our findings, we propose the
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following algorithm (Figure 3). If SCN cannot confidently be distinguished from MCN
or IPMN, the patient should undergo resection. When the diagnosis of SCN is
confidently determined based on clinical and radiographic evidence, perhaps only
symptomatic tumors should be resected. If the decision is made to avoid resection
initially, we do recommend serial imaging at a 6 to 12 months interval, with resection for
growth (more than 1 cm change in diameter) or the development of symptoms. Post
resection, gross and microscopic review of the neoplasm should document not only the
presence or absence of metastases, but also any locally aggressive growth. For
neoplasms exhibiting this rare characteristic, patients should be counseled that although
in most cases SCNs are cured with primary resection, a small sub-population of cases
may recur, and may require additional imaging follow-up and treatment, as indicated.
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Total patients
Sex
Male
Female
Age (years)
Symptomatic
Abdominal pain
Weight loss
Nausea/vomiting
Jaundice
Gastrointestinal bleed
Operation
Distal pancreatectomy, splenectomy
Whipple
Central pancreatectomy
Local resection or enucleation
Total pancreatectomy
Tumor size (cm)
Operative time (minutes)
Hospital stay (days)
Death
Major complication
Hemorrhage
Pancreatic leak
Bile leak
Retained operative material
Minor complication
Wound infection
Delayed gastric emptying
Postoperative ileus
Arrhythmia
Other infection
Final pathologic diagnosis
Serous cystadenoma
Serous cystadenocarcinoma

n (%)
158

Mean + SD

70 (25)
118 (75)
62.1 + 13.2
101 (64)
75 (47)
22 (14)
10 (6)
6 (4)
3 (2)
75 (47)
65 (41)
9 (6)
5 (3)
4 (3)
5.1 + 3.7
277.5 + 117.4
11.3 + 8.9
1 (0.6)
29 (18)†
2 (1.2)
21 (13)
5 (3)
1 (0.6)
52 (33)*
8 (5)
5 (3)
4 (2)
8 (5)
21 (12)
156 (98)
2 (2)**

TABLE 1: Patient characteristics. †Patients greater than 65 years showed a
trend toward fewer major complications (OR = 0.36, P = .09). *Men had
significantly more minor complications than women (OR = 3.74, p = .008).
** One patient who was diagnosed with serous cystadenoma on initial
resection later recurred and was therefore re-diagnosed with
cystadenocarcinoma.

3 65 years

> 65 years

p value

Number of patients

89

69

Major Complications (total)
Hemorrhage
Pancreatic leak
Bile leak
Retained operative material

19
1
14
3
1

9
1
7
2
0

.088

Minor Complications (total)
Wound infection
Delayed gastric emptying
Postoperative ileus
Small bowel obstruction*
Arrhythmia
Deep Vein Thrombosis
Other infection

31
4
3
3
3
5
1
12

19
4
2
1
0
3
0
9

N.S.

TABLE 2: Complications compared with age of patients. Note that patients greater than
65 years showed a trend toward fewer major complications (OR = 0.36, P = .09).

Male

Female

p value

Number of patients

40

118

Major Complications (total)
Hemorrhage
Pancreatic leak
Bile leak
Retained operative material

6
0
6
0
0

23
2
15
5
1

N.S.

Minor Complications (total)
Wound infection
Delayed gastric emptying
Postoperative ileus
Small bowel obstruction*
Arrhythmia
Deep Vein Thrombosis
Other infection

17
3
1
1
1
3
1
7

33
5
4
3
2
5
0
14

.008

TABLE 3: Complications compared with patient gender. Note that males had
significantly more minor complications than women (OR = 3.74, p = .008).

FIGURE LEGENDS

b
FIGURE 1: Computed tomography (CT) scans of two patients, each with serous
cystadenoma of the pancreas. The image on the right is from a 64 year old female who
presented with abdominal pain. Her 10 cm neoplasm in the head of the pancreas was
resected with a Whipple procedure without complication. The image on the left is from a
59 yo female who presented with pain and “fullness.” Her 27 cm mass originating from
the tail of the pancreas was resected with a distal pancreatectomy and splenectomy
without complication.
FIGURE 2: Locally aggressive SCN. Although classically benign, SCNs may rarely
exhibit locally aggressive behavior. In one patient, tumor compresses the pancreatic duct
(a). On microscopic examination, this neoplasm exhibits bland histological appearance,
lacking both architectural and cytologic atypia (b). However, this SCN shows
uncommon locally aggressive behavior by growing up against and into a neighboring
lymph node (arrows).
FIGURE 3: Proposed approach to the patient with a cystic neoplasm of the pancreas.
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